News & Events
-
December 17, 2018
CPTR Newsletter – December 2018
CPTR Newsletter – December 2018 In this issue: In the Spotlight: TB-ReFLECT Manuscript Published Updates to the TB-PACTS Clinical Trial Data Repository Project Highlights: Application of the HFS-TB to Inform Regimen Development Programs Collaboration to Expand ReSeqTB Clinical Data Sets Supporting Global Surveillance of TB Resistance Progress with Regulatory Authorities LAM Biomarker Notes...... -
November 8, 2018
Profiles in Business with Tucson Metro Chamber
C-Path President and CEO Martha Brumfield, Ph.D., talks about today’s drug discovery process, C-Path’s global impact and what’s next for the organization on the Tucson Metro Chamber’s Profiles in Business podcast.
Listen Now.
-
September 6, 2018
Doris Duke Charitable Foundation Awards Grant to Critical Path Institute to Advance Therapies for Sickle Cell Disease
Contacts: Kissy Black, Critical Path Institute kissyblack@lotosnile.com, 615.298.1144 Kristin Roth-Schrefer, Communications Director kschrefer@ddcf.org, 212.974.7003 Nina Chung, Communications Associate nchung@ddcf.org, 212.974.7006 Critical Path Institute (C-Path) Will Plan a Consortium of Stakeholders Focused on Developing Therapies for Sickle Cell Disease NEW YORK, September 6, 2018 — In a continuing effort to spur advancements in treating...... -
August 10, 2018
CPAD Has Two Posters Accepted to Alzheimer’s Association International Conference
The Alzheimer’s Association International Conference (AAIC) is the largest annual scientific meeting with focus on Alzheimer disease (AD). More than 6,500 researchers and participants from pharma, academia, patent-advocacy organizations and other groups came together in Chicago between July 22nd and 26th to exchange the latest developments and research results. Each year, on behalf of our...... -
August 10, 2018
Evidence-Based Treatment Decisions In Transplantation: The Right Dose & Regimen for the Right Patient/Individualized Treatment
The following originally appeared on fda.gov: Summary: The Food and Drug Administration is announcing the following public workshop titled “Evidence-Based Treatment Decisions In Transplantation: The Right Dose & Regimen for the Right Patient/Individualized Treatment. This public workshop is planned and presented in collaboration with the Transplant Therapeutics Consortium (TTC), a public-private partnership between the FDA, transplantation......